Traws Pharma Inc (TRAW)

Currency in USD
1.585
-0.055(-3.38%)
Real-time Data·
TRAW Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TRAW is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.4701.990
52 wk Range
0.97019.440
Key Statistics
Prev. Close
1.64
Open
1.88
Day's Range
1.47-1.99
52 wk Range
0.97-19.44
Volume
1.16M
Average Volume (3m)
1.17M
1-Year Change
-82.27%
Book Value / Share
1.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TRAW Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Traws Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Traws Pharma Inc Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Traws Pharma Inc Earnings Call Summary for Q2/2025

  • Revenue surged to $2.7M in Q2 2025, up from $57K in Q2 2024; stock rose 17% premarket
  • Net loss narrowed to $900K from $123.1M year-over-year; R&D expenses decreased to $2.3M
  • Cash position at $13.1M, down from $21.3M at end of 2024; company maintains healthy current ratio of 1.81
  • EPS forecasts for FY2025 and FY2026 set at $30.31 and $62.39 respectively; profitability expected this year
  • COVID-19 phase two study results expected by end of 2025; ongoing discussions with FDA and BARDA
Last Updated: 14/08/2025, 14:32
Read Full Transcript

Compare TRAW to Peers and Sector

Metrics to compare
TRAW
Peers
Sector
Relationship
P/E Ratio
−0.3x−4.1x−0.5x
PEG Ratio
−0.010.200.00
Price/Book
1.5x−0.1x2.6x
Price / LTM Sales
38.7x2.7x3.3x
Upside (Analyst Target)
265.9%70.8%40.3%
Fair Value Upside
Unlock16.8%4.7%Unlock

Earnings

Latest Release
May 15, 2025
EPS / Forecast
2.09 / -0.265
Revenue / Forecast
57.00K / --
EPS Revisions
Last 90 days

TRAW Income Statement

People Also Watch

14.57
OSCR
-2.44%
0.519
WINT
-3.23%
20.090
CPRX
-0.50%
3.70
ALT
-1.01%

FAQ

What Stock Exchange Does Traws Pharma Trade On?

Traws Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Traws Pharma?

The stock symbol for Traws Pharma is "TRAW."

What Is the Traws Pharma Market Cap?

As of today, Traws Pharma market cap is 8.57M.

What Is Traws Pharma's Earnings Per Share (TTM)?

The Traws Pharma EPS (TTM) is -11.22.

From a Technical Analysis Perspective, Is TRAW a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Traws Pharma Stock Split?

Traws Pharma has split 4 times.

How Many Employees Does Traws Pharma Have?

Traws Pharma has 7 employees.

What is the current trading status of Traws Pharma (TRAW)?

As of 14 Aug 2025, Traws Pharma (TRAW) is trading at a price of 1.59, with a previous close of 1.64. The stock has fluctuated within a day range of 1.47 to 1.99, while its 52-week range spans from 0.97 to 19.44.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.